Abstract
A tremendous research on Poly (ADP-ribose) polymerase (PARP) pertaining to cancer and ischemia is in very rapid progress. PARP’s are a specific class of enzymes that repairs the damaged DNA. Recent findings suggest also that PARP-1 is the most abundantly expressed nuclear enzyme which involves in various therapeutic areas like inflammation, stroke, cardiac ischemia, cancer and diabetes. The current review describes the overview on clinical candidates of PARP1 and its current status in clinical trials. This paper also covers identification of potent PARP1 inhibitors using structure and ligand based pharmacophore models. Finally 36 potential hits were identified from the virtual screening of pharmacophore models and screened for PARP1 activity. 15 actives were identified as potent PARP1 inhibitors and further optimization of these analogues are in progress.
Keywords: Cancer, docking, glide, PARP1, pharmacophore, virtual screening.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors
Volume: 14 Issue: 17
Author(s): Sardar Shamshair Singh, Jagarlapudi A.R.P. Sarma, Lakshmi Narasu, Raveendra Dayam, Shili Xu and Nouri Neamati
Affiliation:
Keywords: Cancer, docking, glide, PARP1, pharmacophore, virtual screening.
Abstract: A tremendous research on Poly (ADP-ribose) polymerase (PARP) pertaining to cancer and ischemia is in very rapid progress. PARP’s are a specific class of enzymes that repairs the damaged DNA. Recent findings suggest also that PARP-1 is the most abundantly expressed nuclear enzyme which involves in various therapeutic areas like inflammation, stroke, cardiac ischemia, cancer and diabetes. The current review describes the overview on clinical candidates of PARP1 and its current status in clinical trials. This paper also covers identification of potent PARP1 inhibitors using structure and ligand based pharmacophore models. Finally 36 potential hits were identified from the virtual screening of pharmacophore models and screened for PARP1 activity. 15 actives were identified as potent PARP1 inhibitors and further optimization of these analogues are in progress.
Export Options
About this article
Cite this article as:
Singh Shamshair Sardar, Sarma A.R.P. Jagarlapudi, Narasu Lakshmi, Dayam Raveendra, Xu Shili and Neamati Nouri, A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors, Current Topics in Medicinal Chemistry 2014; 14 (17) . https://dx.doi.org/10.2174/1568026614666140929152123
DOI https://dx.doi.org/10.2174/1568026614666140929152123 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Current Drug Metabolism Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update
Current Cancer Drug Targets Curbing the Deregulation of Glycosylation in Tongue Carcinoma Cells with Natural Compounds
Anti-Cancer Agents in Medicinal Chemistry Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
Anti-Cancer Agents in Medicinal Chemistry The “Invisible Proteome”: How to Capture the Low-Abundance Proteins Via Combinatorial Ligand Libraries
Current Proteomics Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Chemistry and Relevant Biomimetic Applications of Group 6 Metals Systems Supported by Scorpionates
Current Bioactive Compounds